Advertisement

Topics

twoXAR Announces Preclinical Proof-of-Concept Data on Type 2 Diabetes Candidate

17:37 EDT 19 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Study demonstrates the power of artificial intelligence-enabled approaches in accelerating early-stage drug discovery for new treatments in type 2 diabetes twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutic...

Other Sources for this Article

for twoXAR, Inc.
Colin Sanford, 415-946-1094
csanford@purecommunications.com

NEXT ARTICLE

More From BioPortfolio on "twoXAR Announces Preclinical Proof-of-Concept Data on Type 2 Diabetes Candidate"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...